Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

GLP-1 boom: no signs of slowing as sales continued to surge in 4Q24

Sales of top brands from both Lilly and Novo recorded all-time highs, again

March 5, 2025 10:41 PM UTC

The GLP-1 market continued to expand in 4Q24, with sales of the top four products, two each from Novo Nordisk and Eli Lilly, reaching new highs.

Diabetes drug Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) maintained both its lead position and upward growth trajectory. The once-weekly subcutaneous therapy has brought in over $4 billion in sales in each of the last five quarters. Its annual sales grew 25% last year, to over $17 billion. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article